Subunit vaccine

A subunit vaccine is a vaccine that contains purified parts of the pathogen that are antigenic, or necessary to elicit a protective immune response. Subunit vaccine can be made from dissembled viral particles in cell culture or recombinant DNA expression, in which case it is a recombinant subunit vaccine. A "subunit" vaccine doesn't contain the whole pathogen, unlike live attenuated or inactivated vaccine, but contains only the antigenic parts such as proteins, polysaccharides or peptides. Because the vaccine doesn't contain "live" components of the pathogen, there is no risk of introducing the disease, and is safer and more stable than vaccines containing whole pathogens. Other advantages include being well-established technology and being suitable for immunocompromised individuals. Disadvantages include being relatively complex to manufacture compared to some vaccines, possibly requiring adjuvants and booster shots, and requiring time to examine which antigenic combinations may work best. The first recombinant subunit vaccine was produced in the mid-1980s to protect people from Hepatitis B. Other recombinant subunit vaccines licensed include Engerix-B (hepatitis B), Gardasil 9 (Human Papillomavirus), Flublok(influenza), Shingrix (Herpes zoster) and Nuvaxovid (Coronavirus disease 2019). After injection, antigens trigger the production of antigen-specific antibodies, which are responsible for recognising and neutralising foreign substances. Basic components of recombinant subunit vaccines include recombinant subunits, adjuvants and carriers. Additionally, recombinant subunit vaccines are popular candidates for the development of vaccines against infectious diseases (e.g. tuberculosis, dengue) Recombinant subunit vaccines are considered to be safe for injection. The chances of adverse effects vary depending on the specific type of vaccine being administered. Minor side effects include injection site pain, fever, and fatigue, and serious adverse effects consist of anaphylaxis and potentially fatal allergic reaction.

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Related concepts (14)

Related courses (5)

Related lectures (17)

Related MOOCs (5)

ChE-433: Biotechnology lab (for CGC)

This laboratory-training course is designed to give students a comprehensive insight into laboratory research techniques in the field of biotechnology and pharmaceutical biotechnology with practices e

BIOENG-399: Immunoengineering

Immunoengineering is an emerging field where engineering principles are grounded in immunology. This course provides students a broad overview of how engineering approaches can be utilized to study im

BIO-614: Practical - Antanasijevic Lab

The students will learn:

how to handle viral protein antigens and antibody samples
how to assemble and purify immune complexes using liquid chromatography
how to image them on an electron

Introduction à l'immunologie (part 1)

Ce cours décrit les mécanismes fondamentaux du système immunitaire pour mieux comprendre les bases immunologiques dela vaccination, de la transplantation, de l’immunothérapie, de l'allergie et des mal

Introduction à l'immunologie (part 2)

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a strain of coronavirus that causes COVID-19, the respiratory illness responsible for the COVID-19 pandemic. The virus previously had the provisional name 2019 novel coronavirus (2019-nCoV), and has also been called human coronavirus 2019 (HCoV-19 or hCoV-19). First identified in the city of Wuhan, Hubei, China, the World Health Organization designated the outbreak a public health emergency of international concern from January 30, 2020, to May 5, 2023.

A COVID19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID19). Prior to the COVID19 pandemic, an established body of knowledge existed about the structure and function of coronaviruses causing diseases like severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). This knowledge accelerated the development of various vaccine platforms during early 2020.

Design of Immunogenic Vaccines BIOENG-399: Immunoengineering

Explores the challenges and triumphs in designing immunogenic vaccines, focusing on antigens, adjuvants, and the delivery strategies for effective vaccination.

Design of Immunogenic Vaccines BIOENG-399: Immunoengineering

Explores the design of immunogenic vaccines, boosting immune response through various methods, and addressing challenges in vaccine development.

Treatments and Vaccines BIO-310: Immunology MOOC: Introduction à l'immunologie (part 1)

Discusses treatments, vaccines, and the importance of prevention against severe forms of Covid-19.